MedTrace Logo

Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids

NCT00003686 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-04-03

No results posted yet for this study

Summary

RATIONALE: Pilocarpine may help to relieve dry mouth in patients receiving opioids for cancer therapy. It is not yet known whether pilocarpine is more effective than no further treatment for this condition.

PURPOSE: Randomized phase III trial to determine the effectiveness of pilocarpine in treating patients who have dry mouth caused by opioids.

Conditions

  • Oral Complications
  • Quality of Life

Interventions

DRUG

pilocarpine hydrochloride

Pilocarpine 5 mg po qid x 4 weeks

DRUG

Placebo

Placebo 5 mg po qid x 4 weeks

Sponsors & Collaborators

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • David Warr, MD · Princess Margaret Hospital, Canada

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-22
Primary Completion
2007-11-01
Completion
2008-12-15

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003686 on ClinicalTrials.gov